+Compare
OCGN
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
115.83M

OCGN Ocugen Forecast, Technical & Fundamental Analysis

a company, which engages in the development and commercialization of therapies for eye diseases

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for OCGN with price predictions
08:00 PM EDT Jun 01, 2023

Momentum Indicator for OCGN turns negative, indicating new downward trend

OCGN saw its Momentum Indicator move below the 0 level on May 17, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In of the 100 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for OCGN turned negative on May 24, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for OCGN entered a downward trend on May 30, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .

OCGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OCGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.528) is normal, around the industry mean (24.947). P/E Ratio (0.000) is within average values for comparable stocks, (122.964). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.308). Dividend Yield (0.000) settles around the average of (0.031) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (307.036).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.11B. The market cap for tickers in the group ranges from 365 to 360.75B. NONOF holds the highest valuation in this group at 360.75B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 43%, and the average quarterly price growth was 52%. EFTR experienced the highest price growth at 77%, while CLXT experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was -57% and the average quarterly volume growth was -71%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 50
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

OCGN is expected to report earnings to rise 57.14% to -10 cents per share on August 04

Ocugen OCGN Stock Earnings Reports
Q2'23
Est.
$-0.11
Q1'23
Beat
by $0.04
Q4'22
Est.
$-0.10
Q3'22
Est.
$-0.10
Q2'22
Missed
by $0.01
The last earnings report on May 05 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 4.47M shares outstanding, the current market capitalization sits at 115.83M.
A.I. Advisor
published General Information

General Information

a company, which engages in the development and commercialization of therapies for eye diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11 Great Valley Parkway
Phone
+1 484 328-4701
Employees
84
Web
https://www.ocugen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETCGX39.59N/A
N/A
Eventide Gilead C
HRIOX8.49N/A
N/A
Hood River International Opp Instl
LDMOX12.06N/A
N/A
Lazard Developing Markets Equity Open
LMCCX25.43N/A
N/A
Lord Abbett Mid Cap Stock C
PCVAX10.82N/A
N/A
Virtus NFJ Small-Cap Value A

OCGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCGN has been closely correlated with INO. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if OCGN jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCGN
1D Price
Change %
OCGN100%
-1.80%
INO - OCGN
67%
Closely correlated
-4.44%
BEAM - OCGN
66%
Loosely correlated
+1.91%
EDIT - OCGN
66%
Loosely correlated
+4.03%
VXRT - OCGN
65%
Loosely correlated
+2.46%
SANA - OCGN
63%
Loosely correlated
+1.33%
More

Groups containing OCGN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCGN
1D Price
Change %
OCGN100%
-1.80%
OCGN
(undefined stocks)
70%
Closely correlated
+3.61%